Rznomics Inc.

Rznomics Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government. In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.

Company Details

Employees
13
Founded
-
Address
분당구 판교로 253, 이노밸리c동 801호,korea, Republic Of
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Keywords
성남시.
HQ
성남시, 경기도
Looking for a particular Rznomics Inc. employee's phone or email?

Rznomics Inc. Questions

News

Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics - PR Newswire

Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics PR Newswire

Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation - PR Newswire

Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation PR Newswire

RZ-001 Earns FDA Fast Track Designation in HCC - OncLive

RZ-001 Earns FDA Fast Track Designation in HCC OncLive

Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline - BioSpace

Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline BioSpace

Rznomics to commence RNA editing therapy trial for retinitis pigmentosa - Clinical Trials Arena

Rznomics to commence RNA editing therapy trial for retinitis pigmentosa Clinical Trials Arena

Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact - Fierce Biotech

Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact Fierce Biotech

Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug - BioWorld MedTech

Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug BioWorld MedTech

Adenovirus VA RNAs impair maturation of primary microRNA - Kim - 2023 - The Journal of Gene Medicine - Wiley Online Library

Adenovirus VA RNAs impair maturation of primary microRNA - Kim - 2023 - The Journal of Gene Medicine Wiley Online Library

South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly - The Korea Economic Daily Global Edition

South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly The Korea Economic Daily Global Edition

Rznomics Presents Its Own Circular RNA Platform Technology - PR Newswire

Rznomics Presents Its Own Circular RNA Platform Technology PR Newswire

Top Rznomics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant